Pharmaxis, Boehringer Ingelheim deal

Boehringer Ingelheim received an exclusive option to license worldwide rights to Pharmaxis’ PXS4728A and related molecules. Pharmaxis will receive EUR1.3 million ($1.4 million) for the option, which expires on May 15. PXS4728A, an oral vascular adhesion protein-1 (VAP-1; SSAO) inhibitor, is in Phase I testing to treat inflammatory disease. According to Pharmaxis, Boehringer’s primary interest in the compound is directed at non-alcoholic steatohepatitis (NASH). ...